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 2 
ABSTRACT  23 
Asthma is a common, heterogeneous and serious disease, its’ prevalence has steadily risen in 24 
most parts of the world, and the condition is often inadequately controlled in many patients. 25 
Hence, there is a major need for new therapeutic approaches. Mild-to-moderate asthma is 26 
considered a T-helper cell type-2-mediated inflammatory disorder that develops due to 27 
abnormal immune responses to otherwise innocuous allergens. Prolonged exposure to allergens 28 
and persistent inflammation results in myofibroblast infiltration and airway remodelling with 29 
mucus hypersecretion, airway smooth muscle hypertrophy, and excess collagen deposition. 30 
The airways become hyper-responsive to provocation resulting in the characteristic wheezing 31 
and obstructed airflow experienced by patients. Extensive research has progressed the 32 
understanding of the underlying mechanisms and the development of new treatments for the 33 
management of asthma. Here, we review the basis of the disease, covering new areas such as 34 
the role of vascularisation and microRNAs, as well as associated potential therapeutic 35 
interventions utilising reports from animal and human studies. We also cover novel drug 36 
delivery strategies that are being developed to enhance therapeutic efficacy and patient 37 
compliance. Potential avenues to explore to improve the future of asthma management are 38 
highlighted. 39 
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Introduction 43 
Asthma is a major international health issue affecting >330 million people worldwide.  There 44 
have been significant increases in worldwide prevalence at an annual rate of 1.4% (4.2 million) 45 
in children and 2.1% (6.3 million) in adults (Genuneit et al. 2017). Latin America, Australasia, 46 
Europe, North America and South Africa have the highest prevalence (>20%), whereas Asian 47 
countries have relatively low rates (2-4%) (Asher and Ellwood 2014; Asher et al. 2006; Beasley 48 
1998; Janson et al. 2001; Zock et al. 2006). Although children make up the majority of asthma 49 
patients, they have relatively low mortality rates (0.02% in-hospital asthma mortality). Older 50 
patients are more susceptible to asthma exacerbations and mortality risk increases with 51 
increasing age, and the elderly (>75 years) have the highest mortality (1.9% in-hospital 52 
mortality) (Krishnan et al. 2006). 53 
 54 
Characteristic features of asthma  55 
Asthma pathogenesis is underpinned by the principal components of airway inflammation and 56 
airway remodelling that combine to induce key symptoms like shortness of breath, chest 57 
tightness, cough, wheezing and airway hyperresponsiveness (AHR) (Hansbro et al. 2017). 58 
These events are linked to excessive reactions to normally innocuous allergen(s) that induce 59 
airway inflammation, AHR and reversible airway obstruction (Cahill et al. 2017; Galli 2017). 60 
Asthma symptoms are worsened by environmental and physical factors, such as infection, air 61 
pollution, smoke, climate change and physical exercise (Kim et al. 2015; Starkey et al. 2013b). 62 
When exacerbated by risk factors, patients have accelerated loss of lung function, and some 63 
develop irreversible airway obstruction. These exacerbations activate multiple parallel 64 
pathways that initiate both inflammation and tissue remodelling that can also induce resistance 65 
to mainstay corticosteroid treatments (Galvão et al. 2020; Kim et al. 2015). These events 66 
narrow the airways and further deteriorate lung function (Figure 1) (Wisnivesky et al. 2017). 67 
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 68 
Asthma is now considered a complex syndrome rather. Over the last decade we have moved to 69 
categorising patients from generic symptoms towards patient-specific symptoms and/or 70 
severity based on clinical phenotypes and inflammatory endotypes (Kaur and Chupp 2019; 71 
Lötvall et al. 2011). Almost 20+ years ago, Wenzel et al. categorised asthma into T2-high or 72 
T2-low based on airway eosinophil counts (Wenzel et al. 1999). Currently, asthma endotypes 73 
include T2-high or non-T2, eosinophilic, neutrophilic, granulocytic and paucigranulocytic 74 
amongst other classifications. T2-high asthma is further categorised into atopic, late onset or 75 
aspirin-exacerbated respiratory disease (Kuruvilla et al. 2019). Non-T2 high asthma is 76 
subdivided depending upon the type of stimuli, with smoke exposure, non-atopic asthma, 77 
obesity-related asthma and asthma associated with old age (Kuruvilla et al. 2019). Improved 78 
understanding of underlying mechanisms of asthma phenotypes and endotypes will enable the 79 
optimisation of the therapeutic options available to clinicians and patients. 80 
 81 
Airway Inflammation 82 
Through the interaction of multifactorial processes, numerous cell types compromise the 83 
respiratory system in asthma. These include neutrophils, macrophages, dendritic cells (DCs), 84 
mast cells, and airway epithelial cells (AECs), although eosinophils are thought to be pivotal 85 
in allergic asthma (Djukanovic 2002; Shukla et al. 2019). During the development of asthma, 86 
a myriad of inflammatory mediators, mostly cytokines and chemokines, are secreted and 87 
induce the influx of inflammatory cells to the airways (Djukanovic 2002; Shukla et al. 2019) . 88 
 89 
T-helper (Th) cells have established roles in asthma pathogenesis. It is proposed that subsets 90 
of innate lymphoid cells (ILCs) and DCs are induced that promote the development of Th type-91 
2 (Th2) cells, which then elicit uncontrolled immune responses in the lungs (Romagnani 2000; 92 
Starkey et al. 2019). This is supported by a distinct change towards a Th2 cytokine profile in 93 
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mild to moderate forms of the disease (Barnes 2001; Larché et al. 2003). Activated Th2 cells 94 
are widely accepted to cause tissue remodelling and AHR in eosinophilic asthma (Hansbro et 95 
al. 2017).  96 
 97 
Several external stimuli, including cigarette smoke and other environmental exposures, and 98 
bacterial and viral infections skew the immune response to more pro-inflammatory Th1/Th17-99 
dominant responses through a range of different mechanisms that characterises more severe 100 
corticosteroid-resistant asthma (Essilfie et al. 2015; Essilfie et al. 2012; Kim et al. 2017b). 101 
Exposure to cigarette smoke has been linked to neutrophilic subtypes of asthma with 102 
pronounced airway remodelling and non-responsiveness to corticosteroids (Polosa and 103 
Thomson 2013). Several studies suggest that repeated exposures to other inhalants, such as 104 
diesel exhaust, occupational chemicals and fumes, and air pollutants (e.g., PM2.5) could also 105 
result in neutrophilic asthma (Douwes et al. 2002; Esteban-Gorgojo et al. 2018; Simpson et al. 106 
2006). Indeed, although asthma is classically categorized by eosinophilic inflammation and can 107 
be managed by corticosteroids, asthma driven by non-eosinophilic inflammation is often 108 
resistant to corticosteroid treatment, which is collectively known as non-eosinophilic 109 
corticosteroid-resistant asthma (Esteban-Gorgojo et al. 2018). This phenotype is often 110 
presented with similar symptoms that occur in other asthma patients, however, their severity is 111 
increased higher and including more severe lung function impairment (Adcock et al. 2008; 112 
Barnes and Adcock 2009). Although the origin of this particular type of asthma is yet to be 113 
fully elucidated, bacterial infections are thought to be another underlying cause (Essilfie et al. 114 
2011; Essilfie et al. 2012; Horvat et al. 2010a; Horvat et al. 2010b). Respiratory pathogens, 115 
such as Chlamydia muridarum, Chlamydia pneumoniae, and Haemophilus influenzae, can 116 
induce respiratory symptoms that are co-related with this phenotype, including neutrophilic 117 
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airway inflammation, airway hyperresponsiveness, and poor response towards steroid-based 118 
therapy (Essilfie et al. 2011; Essilfie et al. 2012; Horvat et al. 2010a; Horvat et al. 2010b).  119 
 120 
Airway obstruction 121 
AHR and airway obstruction in asthma causes premature closure of the large airways and, 122 
hence, increases airway resistance that reduces the expiratory flow rate and the capacity to 123 
expel air (Hansbro et al. 2017). The obstructive effects are challenging to overcome but the 124 
body can compensate for these alterations by dynamic hyperinflation. This helps to increase 125 
blood oxygen levels but reduces the blood concentration of carbon dioxide, causing respiratory 126 
alkalosis (Fireman 2003; Frieri 2005). Hyperinflation may also generate high intra-pleural and 127 
intra-alveolar pressures, reducing blood oxygenation rate and distorting the pulmonary 128 
circulation (Fireman 2003). Persistent lung hyperinflation progressively reduces blood oxygen 129 
concentration and leads to hypoxia (Fireman 2003; Frieri 2005). Failure to adequately treat 130 
asthma exacerbations can cause collapse of the respiratory system as a consequence of all of 131 
these events, increasing mortality risk. 132 
 133 
Inflammatory cascades  134 
Allergic asthma can be categorised into three distinct phases: induction-, early- and late-phase 135 
asthmatic reactions (Shastri et al. 2014). It is well accepted that airborne antigens, such as 136 
allergens, microbes, and viruses, act as stimulants and irritate AECs (Cahill et al. 2017; Galli 137 
2017). Asthmatic inflammation results from a cascade of events (Figure 2). Briefly, inflamed 138 
AECs secrete thymic stromal lymphopoietin (TSLP) and cytokines, such as interleukin (IL)-139 
33, that activate DCs (Mitchell and O’byrne 2017), which are vital in polarising naive Th cells 140 
through the presentation of immunogenic antigens (Kaiko et al. 2008a; Kaiko et al. 2008b). 141 
DCs also interact with interstitial lung macrophages and T-cells through complex 142 
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interconnected networks involving major histocompatibility complexes and T-cell receptors 143 
(TCRs) (Frieri 2005; Yang et al. 2012), leading to the release of IL-4, which triggers the 144 
activation of Th2 cells. Th2 cells further activate Th9 and B-cells via the release of IL-4 and 145 
IL-13 (Hansbro et al. 2017). IL-4 and IL-13 promote remodelling of the asthmatic airways 146 
involving mucus hypersecretion, smooth muscle proliferation, and myofibroblast 147 
differentiation (Barnes 2001; Shastri et al. 2015a). Notably, IL-13 downregulates the 148 
production of pro-Th1 cytokines, such as IL-12 (Starkey et al. 2013a). It also induces a CD40-149 
dependent switch from immunoglobulin G (IgG) to IgE and, hence, increases IgE synthesis in 150 
B-cells (Romagnani 2000). Both Th9- and B-cells activate mast cells via IL-9 and IgE 151 
production. Binding of IgE to its’ receptors on mast cells triggers their degranulation, leading 152 
to the release of pro-inflammatory mediators, including histamine and leukotrienes (Holgate 153 
2000). Th2 cells also secrete IL-5, which activates and recruits eosinophils to the airways, and 154 
promotes their survival (Brusselle et al. 2013; Shastri et al. 2015b). Activated eosinophils can 155 
further elicit inflammation by secreting pro-inflammatory cytokines and leukotrienes 156 
(Brusselle et al. 2013). These factors induce AHR and constrict the airways (Brusselle et al. 157 
2013). Activated DCs and naive Th cells can also activate Th17 cells via the release of 158 
inflammatory mediators, including IL-23 and IL-6 (Hansbro et al. 2017), and these cells in turn 159 
recruit and activate neutrophils. Neutrophils are also activated by damaged AECs through the 160 
secretion of the chemokine CXCL1 (Ennis 2003; Hallstrand et al. 2014). Neutrophils are the 161 
most abundant leukocytes in the airway mucosa and have a major role in tissue remodelling. 162 
 163 
Ongoing inflammation results in the late-phase asthmatic response characterised by permanent 164 
structural changes, including deposition of extracellular matrix (ECM) proteins around the 165 
airway smooth muscle (ASM), resulting in ASM hypertrophy and hyperplasia, sub-basement 166 
membrane fibrosis and mucus cell metaplasia (Liu et al. 2017). These changes are collectively 167 
termed airway remodelling. Various ECM proteins are present at abnormal levels in asthmatic 168 
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patients and contribute to airway remodelling including collagen, fibronectin, tenascin, fibulin, 169 
and periostin (Lau et al. 2010; Liu et al. 2016; Liu et al. 2017). Differences in the composition 170 
of ECM proteins may distinguish specific type(s) and severity of asthma, and predict responses 171 
of patients to monoclonal antibody (mAB) treatment. 172 
 173 
Impact of airway vascularisation  174 
The presence of abnormal vasculature in the pulmonary sub-epithelial vascular network of the 175 
airways may also play pivotal roles in asthma pathogenesis (Grigoras et al. 2012). Increases in 176 
the amount, density, and area of microvessels occur in the sub-epithelial zone of asthmatic 177 
airways (Chetta et al. 2003; Grigoras et al. 2012; Hashimoto et al. 2005; Hoshino et al. 2001a; 178 
Hoshino et al. 2001b; Huang et al. 2015). Moreover, studies have revealed the involvement of 179 
pro-angiogenesis factors, including vascular endothelial growth factor (VEGF) in sputum, 180 
bronchoalveolar lavage (BAL) fluid and bronchial tissue in asthma (Table 1) (Abdel-Rahman 181 
et al. 2006; Asai et al. 2003; Meyer and Akdis 2013). VEGF induces the proliferation and 182 
growth of endothelial cells, and is produced by various inflammatory cells, including 183 
eosinophils, macrophages, and mast cells (Bakakos et al. 2016). There are different isoforms 184 
of VEGF; VEGF-A, VEGF-B, VEGF-C, and VEGF-D (Ferrara 2007). Moreover, various 185 
receptor tyrosine kinases are known to bind VEGF and induce angiogenesis, including VEGF 186 
receptor (VEGFR)1 and VEGFR2. Both are expressed in most endothelial and haemopoietic 187 
stem cells, but they have different cellular functions (Meyer and Akdis 2013). VEGFR2 is the 188 
primary receptor that promotes angiogenesis; whereas VEGFR1 is proposed to act as a 189 
competitive inhibitor that binds to VEGF but does not promote angiogenesis, hence reducing 190 
VEGF-VEGFR2 binding (Meyer and Akdis 2013).  The degree of vascularisation in asthmatic 191 
airway tissue is also increased and is dependent on the severity of exacerbations (Hashimoto et 192 
al. 2005; Salvato 2001). Notably, there is also a concomitant relationship between percentage 193 
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vascularisation, lung function, and severity of asthma exacerbations (Grigoras et al. 2012; 194 
Hoshino et al. 2001a; Hoshino et al. 2001b). Understanding the underlying mechanisms leading 195 
to increased vascularisation may help elucidate its role in airway inflammation and altered lung 196 
function in asthma. 197 
 198 
Two types of vascular systems exist in respiratory tissues, the pulmonary system (low pressure, 199 
undertakes gas exchange) and the bronchial circulation (high pressure system that supplies 200 
nutrients and oxygenated blood) (Zanini et al. 2010). The bronchial circulation consists of the 201 
inner vascular plexus in the lamina propria and the outer plexus in the adventitia (Zanini et al. 202 
2010). The vascularisation phenomenon in lungs is restricted to microvessels or capillaries 203 
(Asai et al. 2003; Hashimoto et al. 2005; Kanazawa et al. 2007; Kanazawa et al. 2004). 204 
Emerging evidence demonstrates the presence of abnormal vascular structure in the internal 205 
plexus within the sub-epithelial, sub-mucosa, and lamina propria (Asai et al. 2003; Hashimoto 206 
et al. 2005; Kanazawa et al. 2007; Kanazawa et al. 2004). The vasculature in the outer plexus 207 
is poorly studied due to the difficulty in isolating such tissues. Angiogenesis is an important 208 
mechanism leading to vascularisation. Physiological challenges to the airways may increase 209 
the expression of pro-angiogenic mediators, like VEGF, thereby promoting angiogenesis in 210 
affected tissues (Kim 2017). Endothelial cells in airway tissues also release endogenous 211 
proteases, such as matrix metalloproteinases (MMPs), which distort vessel membranes and 212 
induce vasodilation (Carmeliet 2000; Carmeliet 2005). This leads to the influx of plasma 213 
proteins and cells into the tissues, which promote the formation of endothelial tip cells 214 
(Carmeliet 2000; Carmeliet 2005). This process leads to the creation of new vessels, and the 215 
establishment of additional vascular networks (Chung and Ferrara 2011; Hellström et al. 2001; 216 
Silva et al. 2008; Yoo and Kwon 2013). Further studies need to identify other potential 217 
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mechanisms of vascularisation in asthmatic airways, such as vasculogenesis, which occurs in 218 
chronic obstructive pulmonary disease (COPD) and pneumonia. 219 
 220 
The formation of extra microvessels provides an additional route for inflammatory mediators 221 
to translocate to the airway epithelium and lumen, resulting in sustained inflammation and 222 
aggravation of airway obstruction (Harkness et al. 2015; Narayanan et al. 2016). The excess 223 
production of mediators and influx of inflammatory cells induces vasodilation and plasma 224 
engorgement (Page et al. 2017). Vascularisation may also alter tissue structure (Chakir et al. 225 
2003; Niimi et al. 2003). Consequences of these events include airway fibroblast hyperactivity, 226 
mucus hypersecretion, and ASM hypertrophy (Benayoun et al. 2003; Harkness et al. 2015; 227 
Zanini et al. 2010). In combination, these responses thicken the airway walls, further worsening 228 
lumen narrowing and declines in lung function. 229 
 230 
Targeted therapeutic strategies 231 
Despite major advances in understanding the pathophysiology of asthma, morbidity rates 232 
continue to rise, and current therapies, such as corticosteroids, have adverse effects. Most 233 
importantly, a significant population of asthmatic patients do not respond to corticosteroids 234 
(Green et al. 2002). However, recent progress in understanding the cellular and molecular 235 
mechanisms have shed new light on the development of novel therapeutic strategies for the 236 
management of severe asthma (Nixon et al. 2017). 237 
 238 
Among various therapeutic strategies, the use of new biological agents, mostly discovered 239 
using mouse models and which target key inflammatory mediators, demonstrates significant 240 
potential. To date, omalizumab and mepolizumab, which are neutralising monoclonal 241 
antibodies (mAbs) against IgE and IL-5, respectively, are approved by the US FDA and EMA 242 
(Pelaia et al. 2012; Wenzel 2012). Similarly, therapeutic strategies against other inflammatory 243 
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mediators involved in asthma pathogenesis are in clinical trials (Table 2). Indeed, there are 244 
numerous novel asthma therapies that are either available or under clinical trials. 245 
 246 
Anti-IgE 247 
IgE has been a target for the treatment of allergic diseases for many years (Ishizaka and Ishizaka 248 
1967; Pelaia et al. 2008). After allergen-challenge, antigen-activated IgE binds to Fc receptors 249 
on mast cells and promotes their activation (Pelaia et al. 2012). Consequently, mast cells 250 
undergo degranulation and release preformed pro-inflammatory mediators (Pelaia et al. 2012). 251 
Omalizumab (anti-IgE mAb) reduced asthma exacerbations showing that IgE suppression may 252 
be beneficial in asthma. Omalizumab is a recombinant antibody containing a complementarity-253 
determining region, which is obtained from an anti-IgE antibody in mice (Presta et al. 1993). 254 
High-affinity binding of omalizumab to IgE constrains the interaction of the antibody with mast 255 
cells, thus preventing mast cell degranulation (Shields et al. 1995). In clinical studies, 256 
omalizumab treatment reduced free serum IgE concentrations by 99%, and suppressed new IgE 257 
production (Tomkinson et al. 2001). Furthermore, it also decreased the efficacy of antigen-258 
presenting cell interactions with naïve Th cells (Novak et al. 2003). Recently, omalizumab was 259 
found to be effective in reducing asthma exacerbation rates across a wide range of eosinophil 260 
levels (Hanania et al. 2018). Similar beneficial effects were also observed after the 261 
administration of omalizumab in children with severe asthma (Szefler et al. 2018). 262 
Interestingly, a recent study demonstrated the efficacy of omalizumab in improving IFN-α and 263 
IFN-λ release in patients with influenza A virus- and rhinovirus-induced severe allergic asthma, 264 
highlighting the additional potential of omalizumab in exacerbations (Wark et al. 2018). 265 
Furthermore, data from a recent phase III clinical trial (NCT01328886) showed that long term 266 
therapy with omazulimab is safe and effective in children with severe uncontrolled allergic 267 
asthma (Odajima et al. 2017).  268 
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Inhibition of type 2 responses 269 
TSLP and IL-33 blockade 270 
TSLP and IL-33 are produced by AECs in response to exogenous pro-inflammatory stimuli 271 
and are involved in the activation of DCs and the associated cascade of inflammatory events 272 
(Hallstrand et al. 2014). Gauvreau et al., revealed that a human anti-TSLP mAb 273 
(AMG157/MEDI19929; also known as tezepelumab) reduced airway inflammation and 274 
relieved allergen-induced bronchoconstriction in patients with mild asthma in a phase I study 275 
(NCT01405963) (Gauvreau et al. 2014). In a Phase II trial (NCT02054130), tezepelumab 276 
reduced the exacerbation rate in patients with uncontrolled asthma (Corren et al. 2018). 277 
Another antibody, ANB020 (anti-IL-33 mAb) cleared Phase I trials and showed a good 278 
pharmacokinetic, pharmacodynamic, tolerability and safety profile in healthy volunteers 279 
receiving one or multiple doses (Londei et al. 2017). Results from Phase II trials are anticipated 280 
soon. Although anti-TSLP and anti-IL-33 antibodies have clinical potential, carefully 281 
controlled trials are needed to evaluate their true pharmacological applicability and efficacy in 282 
asthma. carefully controlled trials are needed to evaluate their true pharmacological 283 
applicability and efficacy in asthma 284 
 285 
Anti-IL-4 286 
IL-4 contributes significantly to asthma pathophysiology, primarily in the early development 287 
of allergy (Humbert et al. 1997; Kotsimbos et al. 1996). It promotes differentiation of naive Th 288 
cells into Th2 cells and their proliferation, and also contributes to airway tissue remodelling 289 
(Barnes 2006; Barnes 2008; Schipf et al. 2003). Most anti-IL-4 therapies, such as pascolizumab 290 
(anti-IL-4 mAb), are highly effective in suppressing asthma features in vitro and in animal 291 
models (Hansbro et al. 2013). However, these antibodies are typically found to be clinically 292 
ineffective in established asthma in humans (Corry et al. 1996; Zhou et al. 1997). Altrakincept 293 
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(soluble humanised IL-4 inhibitor) blocked airway eosinophil infiltration and mucus 294 
hypersecretion in allergen-challenged mice (Henderson et al. 2000). It is safe in moderate 295 
asthma patients and reduces inflammation (Borish et al. 2001; Borish et al. 1999). However, 296 
again the respiratory function of asthma patients was not improved (Borish et al. 2001; Borish 297 
et al. 1999).  Further studies are warranted to improve the anti-IL-4 medications for asthma, 298 
but it is likely more effective as a preventative rather than a treatment. 299 
 300 
Anti-IL-5 301 
IL-5 has important roles in allergen-induced asthma as a mediator of the activation, 302 
proliferation, and maturation of eosinophils (Stirling et al. 2001). Animal studies show that 303 
anti-IL-5 mAb, TRFK-5, reduced eosinophil influx into mouse airways after allergen challenge 304 
(Garlisi et al. 1999), and suppressed AHR in mouse models of asthma (Mauser et al. 1995). 305 
Early clinical trials in mild and chronic asthma with a similar anti-IL-5 mAb, mepolizumab 306 
showed that it is safe (Holgate 2008; Leckie et al. 2000; Tanaka et al. 2004), but therapeutic 307 
efficacy was inconsistent (Leckie et al. 2000; Mauser et al. 1995; Tanaka et al. 2004). Some 308 
patients responded well, those with elevated IL-5/eosinophils, and the levels of eosinophils 309 
were significantly reduced, but likely not sufficiently so, and overall it did not improve 310 
functional endpoints, such as lung function and asthma symptoms. Interestingly, in a phase II 311 
trial (NCT00292877) intravenous administration of mepolizumab to chronic corticosteroid-312 
resistant asthma patients demonstrated clinically reduced blood and sputum levels of 313 
eosinophils, and improved asthma symptoms (Haldar et al. 2009; Nair et al. 2009). A later 314 
phase III clinical trial (NCT01000506) in patients with severe, uncontrolled asthma with 315 
eosinophilic inflammation, mepolizumab met its primary and secondary endpoints by reducing 316 
the number of exacerbations, increasing the time to first exacerbation, and improving FEV1 317 
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and ACQ scores (Pavord et al. 2012). The drug is now approved by FDA and EMA as an add-318 
on maintenance treatment.  319 
 320 
Another anti-IL-5 mAb, benralizumab, had a good therapeutic profile in treating asthma. 321 
Recently, a Phase III trial (NCT02417961), showed that it significantly reduce eosinophil 322 
levels as well as exacerbation rates in asthmatic patients (Ferguson et al. 2018). Another Phase 323 
III study (NCT01928771) revealed that it also significantly improved lung function in patients 324 
with uncontrolled asthma receiving high-doses of inhaled corticosteroids and long-acting β2-325 
agonists (Bleecker et al. 2016). Together these studies show that long-term administration of 326 
anti-IL-5 therapies may be beneficial in asthma. 327 
 328 
Anti-IL-13 and Anti-IL-4Rα 329 
IL-13 is an important inducer of airway tissue remodelling, mucus hypersecretion, and B-cell 330 
proliferation (Doucet et al. 1998; Grünig et al. 1998). In initial clinical trials, tralokinumab 331 
(anti-IL-13 mAb) was safe for intravenous administration, with little or no adverse effects 332 
(Hansbro et al. 2011; Singh et al. 2010). A phase II placebo-controlled study of this mAb 333 
(NCT00873860)  reported  acceptable safety profiles with no serious adverse effects (Piper et 334 
al. 2013). Recently, two phase III clinical trials with tralokinumab, STRATOS 1 335 
(NCT02161757), and STRATOS 2 (NCT02194699) also reported good safety profiles when 336 
administered to patients with severe uncontrolled asthma (Panettieri et al. 2018). 337 
Unfortunately, both STRATOS 1 and STRATOS 2 studies showed inconsistent effects in 338 
reducing exacerbation rates in asthma, raising questions of their efficacy as treatments 339 
(Panettieri et al. 2018). Further trials are warranted to clearly define the effect of tralokinumab 340 
in asthma. Lebrikizumab is another anti-IL-13 mAb which decreased exacerbation rates and 341 
improved FEV1 in asthma, and it also reduced late-phase responses and serum IgE 342 
 15 
concentrations by 48% and 25%, respectively (Hanania et al. 2016; Scheerens et al. 2014). 343 
However, in a subsequent phase III  trial (NCT01868061) various issues with lebrikizumab 344 
treatment were reported (Hanania et al. 2016). Serious adverse events, including aplastic 345 
anaemia and eosinophilia, were reported, and consistent reduction in exacerbation rates was 346 
not observed in asthmatic patients (Hanania et al. 2016). Similar findings were made in another 347 
phase III trial (NCT02104674) where lebrikizumab treatment did not significantly improve 348 
lung function, raising further efficacy questions on specific targeting of IL-13 (Korenblat et al. 349 
2018).  350 
 351 
An anti-IL4Rα mAb, dupilumab, that blocks both IL-4 and IL-13 activity, was found to be 352 
effective in preventing ICS-withdrawal-induced asthma exacerbations and improving FEV1 353 
(Wenzel 2013). Noteworthy observations from anti-IL-13 or anti-IL4Rα trials were that blood 354 
eosinophil counts were moderately increased in patients. This may indicate that blockade of 355 
IL-13 signalling results in the inhibition of eosinophil-recruiting chemokines and, hence, 356 
reduces the migration of these cells from the blood to the lungs (Corren et al. 2017; Hanania et 357 
al. 2016; Nixon et al. 2017; Wenzel 2013). Dupilumab has been recently approved by the FDA 358 
as a treatment for patients with moderate to severe atopic dermatitis, and recently was found to 359 
have similar therapeutic benefit in asthma. In a phase III trial (NCT02414854) in patients with 360 
uncontrolled asthma, dupilumab  significantly reduced exacerbations compared to placebo, and 361 
also improved lung function (Castro et al. 2018). Moreover, both phase IIb (NCT01854047) 362 
and phase III studies (NCT02528214) reported that dupilumab improved lung function and 363 
reduced severe exacerbations in patients with uncontrolled persistent asthma as well as 364 
corticosteroid-dependent severe asthma irrespective of baseline eosinophil counts  (Rabe et al. 365 
2018; Wenzel et al. 2016). 366 
 367 
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Novel agents should be developed and tested against other key proteins and cells, including 368 
mast cells and neutrophils, that are known to play critical roles in asthmatic inflammation, 369 
airway tissue remodelling and severe asthma. Also, drugs that target ECM proteins such as 370 
fibulin-1c, which has been shown to be increased in asthma, should also be assessed (Lau et al. 371 
2010). Its inhibition in mouse models prevented both inflammation and airway remodelling 372 
(Liu et al. 2016). 373 
 374 
Anti-IL-17 375 
Asthma was classically considered as an allergic inflammatory disorder, however, discovery 376 
of non-eosinophilic asthma has revealed the association of neutrophils in severe asthma 377 
pathogenesis. IL-17 is a pro-inflammatory cytokine that is produced by TH17 cells. Its’ 378 
inflammatory roles have been well studied in multiple inflammatory conditions, including 379 
rheumatoid arthritis, COPD, cystic fibrosis, and multiple sclerosis (Miossec et al. 2009). In 380 
asthma, IL-17 is involved in airway remodelling, neutrophilic inflammation, and corticosteroid 381 
resistance in non-eosinophilic asthma (Chang et al. 2012; Chesné et al. 2014; Fogli et al. 2013; 382 
Mizutani et al. 2014; Nadeem et al. 2018; Nakae et al. 2002; Vazquez-Tello et al. 2013; 383 
Vazquez‐Tello et al. 2010; Wakashin et al. 2008). Hence, inhibiting IL-17, may be a possible 384 
treatment for non-eosinophilic asthma. The use of different mouse models has shown efficacy 385 
of anti-IL-17 treatments in the potential management of asthma. Treatment in models of 386 
allergic asthma show improvement in pulmonary inflammation with significant reduction in 387 
neutrophils, eosinophils, T-regulatory cells, and antigen-presenting cells with administration 388 
of anti-IL-17 monoclonal antibody (Camargo et al. 2018; Lovato et al. 2016). Similar effects 389 
were observed in a refractory asthma model also treated with anti-IL-17 (Liang et al. 2018). 390 
However, targeting IL-17 has not yet yielded satisfactory outcomes in clinical trials. 391 
Brodalumab, an IL-17 antagonist, proved to be effective in treating adult patients with 392 
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moderate to severe plaque psoriasis, but failed to demonstrate any treatment effects in patients 393 
with moderate to severe asthma (Beck and Koo 2019; Busse et al. 2013; Khokhlovich et al. 394 
2017). Treatment with secukinumab, a humanized anti-IL-17 monoclonal antibody that showed 395 
excellent clinical outcomes in treating plaque psoriasis, psoriatic arthritis, and rheumatoid 396 
arthritis, was terminated in a phase-II clinical trial in patients with uncontrolled asthma as it 397 
was not effective in the target population (Blanco et al. 2017; ClinicalTrial 2015; Langley et 398 
al. 2014; McInnes et al. 2015).  399 
 400 
Macrolides 401 
Several studies have assessed the use of macrolides for the management of asthma, specifically 402 
bacterial infection-associated non-eosinophilic asthma (Black et al. 2001; Esposito et al. 2004). 403 
Macrolides are antibiotics used to treat bacterial infection by attenuating bacterial protein 404 
biosynthesis and biofilm formation (Xepapadaki et al. 2008). Macrolides also possess anti-405 
inflammatory properties and have been shown to potentiate responsiveness of asthma patients 406 
to corticosteroid therapy (Spahn et al. 2001). Treatment with macrolide (clarithromycin) in a 407 
bacteria-induced severe steroid-resistant severe asthma mouse model demonstrated 408 
antibacterial and anti-inflammatory effects alongside re-sensitization to corticosteroids 409 
(Essilfie et al. 2015).  Likewise, a clinical study also reported the efficacy of clarithromycin in 410 
relieving wheezing in asthma patients co-infected with Chlamydia pneumoniae (Kraft et al. 411 
2002). Moreover, a randomised, double-blind, placebo-controlled clinical trial on asthma 412 
patients receiving macrolide therapy (azithromycin) revealed its immunomodulatory efficacy 413 
by reducing asthma symptoms in non-eosinophilic asthma patients (Gibson et al. 2017). 414 
Notably, administration of azithromycin (500 mg, thrice per week, for 48 weeks) significantly 415 
reduced asthma exacerbations (including severe exacerbations) and sputum eosinophil levels 416 
(Gibson et al. 2017). Although recent evidence suggests largely beneficial effects of 417 
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macrolides, their immunomodulatory functions for asthma management and disease 418 
progression is require further investigation and may induce antibiotic resistance in pathogens. 419 
 420 
Phosphodiesterase (PDE) inhibitors 421 
PDE is an essential enzyme that inhibits cellular signalling molecules like cyclic adenosine 422 
monophoshate (cAMP) and cyclic guanosine monophosphate (cGMP) by degrading their 423 
phosphodiester bonds (Gao et al. 2017; Karish and Gagnon 2006). Thus, by inhibiting PDE, it 424 
is possible to prolong cellular activity initiated by cAMP or cGMP. In asthma, the biosynthesis 425 
of one of the hallmark inflammatory mediators, TNF, is inhibited by cAMP, which is regulated 426 
by PDE (Shah et al. 1995). Hence, inhibiting PDE with inhibitors (PDEIs), could prolong the 427 
activity of cAMP leading to a reduction in the biosynthesis of TNF. Using in-vivo inflammation 428 
models, it was demonstrated that PDEI was able to reduce TNF concentration by up to 85% 429 
compared to sham treatment (Bundschuh et al. 2001; Murad et al. 2017). There are different 430 
types of PDEI available on the pharmaceutical market such as, roflumilast, cilomilast, rolipram, 431 
BAY19-8004, MEM1414, and GSK256066 (Karish and Gagnon 2006). Among them, only 432 
roflumilast is approved for clinical use in treating patients with COPD and was shown to reduce 433 
severe exacerbations and improve lung function (Calverley et al. 2009; Luo et al. 2016). 434 
However, it is not recommended for patients with asthma due to undesirable clinical outcomes. 435 
In multiple clinical trials, PDEI (roflumilast) administration improved lung function in mild to 436 
moderate asthma patients, but failed to have any bronchodilator effects and did not reduce the 437 
allergen-induced inflammation in the early asthma phase (Bateman et al. 2006; Bousquet et al. 438 
2006; Louw et al. 2007). Furthermore, adverse events, such as headache and nausea, were 439 




Histamine is a chemical mediator secreted by mast cells in response to an allergic reaction or 443 
event (Thangam et al. 2018). Under normal conditions, histamine is produced and stored within 444 
mast cells or basophils (Thangam et al. 2018). Upon release, it binds to histamine receptors 445 
expressed in the airways and pulmonary tissues, and subsequently initiates multiple allergic 446 
reactions, leading to mucus hypersecretion, broncho- and vascular constriction (Thangam et al. 447 
2018). However, for these events to occur, the amount of histamine accumulated within the 448 
tissues must overwhelm its counterpart, histamine N-methyl transferase (HMT) (Salomonsson 449 
et al. 2019; Yamauchi and Ogasawara 2019). HMT metabolises airway histamine and has a 450 
significant role in regulating histamine effects on the airways (Yamauchi et al. 1994). Both 451 
histamine and HMT are regulated in a balanced state, and the downstream cascade is only 452 
initiated when the accumulated histamine overwhelms the HMT capability to degrade excess 453 
histamine (Yamauchi et al. 1994). Pharmacological inhibition of HMT with an inhibitor 454 
(SKF91488) exacerbate the contractile response of bronchi towards histamine, hence showing 455 
HMT as a negative regulator of histamine effects on the respiratory system (Curry 1946; 456 
Yamauchi et al. 1994).   457 
 458 
There are 4 known types of histamine receptors (H1, H2, H3, H4) in the respiratory system 459 
(Ahmed et al. 1982; Ichinose and Barnes 1989; Kay et al. 2018; Tucker et al. 1975). Relevant 460 
for asthma H1 receptors mediate the bronchoconstriction of smooth muscle while H2 receptors 461 
are responsible for mucus hypersecretion and vascular dilation (Müller et al. 2006). A potential 462 
therapy to inhibit H1 receptor activity have been developed in the form of antagonists such as 463 
chlorpheniramine and clemastine (Kawauchi et al. 2019; Okubo et al. 2020). Despite being 464 
proven to possess strong biological activity and high specificity for H1 receptors, H1 receptor 465 
antagonists are not generally recommended for asthma treatment. Instead, inhaled 466 
corticosteroids, leukotriene receptor antagonist, and β2-receptor adrenergic agonist are 467 
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recommended (Kawauchi et al. 2019; Okubo et al. 2020). Asthmatic patients receiving 468 
leukotriene receptor antagonist had better recovery in allergen-induced airway obstruction 469 
compared to those who received H1 receptor antagonist. 470 
 471 
Anti-vascularisation therapies 472 
VEGF has a critical role in driving airway vascularisation. As a vascular growth factor, it can 473 
increase MMP activity and the translocation and proliferation of endothelial cells, and hence 474 
plays major roles in promoting angiogenesis in airway tissues (Harkness et al. 2015). VEGF 475 
overexpression in mice leads to prominent airway vascularisation (Baluk et al. 2004). 476 
Administration of VEGF inhibitors, such as sunitinib, effectively suppresses eosinophilic 477 
airway inflammation and airway remodelling in murine asthma models (Huang et al. 2009; Lee 478 
et al. 2002). Moreover, reductions in VEGF levels and peri-bronchial angiogenesis after 479 
treatment with immunostimulatory sequences of DNA (ISSD) was observed in an ovalbumin-480 
induced asthma model (Lee et al. 2006). It has been proposed that ISSD binds to Toll-like 481 
Receptor 9 and inhibits allergen-induced Th2 immune responses, as well as reversing features 482 
of airway remodelling including the development of peri-bronchial fibrosis and increases in 483 
ASM thickness (Lee et al. 2006). Additionally, administration of bevacizumab (recombinant 484 
humanized anti-VEGF mAb) prior to ovalbumin sensitisation inhibited angiogenesis and 485 
reduced airway tissue membrane thickness (Yuksel et al. 2013). 486 
 487 
Administration of endostatin, a 20kDA C-terminal fragment derived from collagen-type XVIII, 488 
in ovalbumin-challenged mice reduced the progression of sub-epithelial angiogenesis, and 489 
relieved pulmonary and lung inflammation (Suzaki et al. 2005). The beneficial effects were 490 
reportedly due to the blockade of VEGF/VEGF receptor signalling. Similar effects were also 491 
observed after the administration of tumstatin (a protein fragment cleaved from collagen type 492 
IV) or synthetic peptides of it (Burgess et al. 2010; Grafton et al. 2014). Tumstatin also 493 
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suppressed inflammatory cell migration, mucus hypersecretion and angiogenesis in ovalbumin-494 
challenged mice (Hutchings et al. 2003). 495 
 496 
Recently, docetaxel, a prodrug (delivered via αvβ3-targeted nanoparticles) that binds to and 497 
stabilises intracellular microtubules, suppressed eosinophil levels and neovascular expansion 498 
in the airways of house dust mite-challenged mice (Lanza et al. 2017). It was proposed that 499 
docetaxel interacts with tubulin and reduces IL-13 and VEGF production. Likewise, in the 500 
same model, the fumagillin-prodrug interacted with methionine aminopeptidase-2 present in 501 
proliferating endothelial cells, and inhibited neovascular expansion in the lungs (Lanza et al. 502 
2017). 503 
 504 
There is still limited knowledge of the optimal means to prevent or reverse the progression of 505 
asthmatic vascularisation. Hence, the development of anti-vascularisation therapies should be 506 
considered as novel therapeutic approaches for asthma. 507 
 508 
Targeting microRNAs (miRNAs) 509 
miRNAs are short non-coding RNAs which control gene expression post-transcriptionally by 510 
directly blocking translation of their target mRNAs or by repressing protein production via 511 
mRNA destabilisation (Dua et al. 2017b; Plank et al. 2015). They regulate many biological 512 
processes (cell differentiation and growth, metabolism, cell signalling, apoptosis) related to 513 
inflammation. They are involved in altering pro-inflammatory responses and also virus-514 
induced effects in human AECs, which are one of the leading causes of asthma exacerbations 515 
(Herbert et al. 2015). Inhibiting the function of specific miRNAs in asthma may be novel 516 
therapeutic approaches (Foster et al. 2013; Greene and Gaughan 2013).  517 
 518 
A recent study showed roles for miR-23b in controlling TGF-β1-induced ASM cell 519 
proliferation by regulating Smad3 and, thereby reducing airway remodelling (Chen et al. 2017). 520 
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Zhou et al., identified miR-155 as a novel target in allergic asthma (Zhou et al. 2016), which 521 
also suppressed chemokine expression (CCL5, CCL11, CCL26, CXCL8, and CXCL10) in 522 
human epithelial cells by inhibiting IL-13 signalling (Matsukura et al. 2016). Others showed 523 
that this miRNA is increased in an ovalbumin-induced mouse model of allergic asthma but its 524 
inhibition with an antagomir did not alter the phenotype, which may be due variable efficacy 525 
in uptake of the inhibitor by different cells (Matsukura et al. 2016; Plank et al. 2015). miR-526 
181b-5p has been identified as a potential biomarker for airway eosinophilia, and controls pro-527 
inflammatory cytokine release by targeting the secreted phosphoprotein 1 (SPP1) gene (Huo et 528 
al. 2016). It also increases inflammation by promoting nuclear factor-κB signalling via the 529 
regulation of p65 and IL-6 (Wang et al. 2015). Similarly, Fan et al., showed in asthma patients 530 
that miR-145 is involved in maintaining the balance between Th1 and Th2 responses by 531 
targeting the runt-related transcription factor 3 (RUNX3), which may be a biomarker for 532 
asthma (Fan et al. 2016). miR-196a2 polymorphisms have also been shown to be involved in 533 
controlling asthma (Hussein et al. 2016). 534 
 535 
An interesting study involving toluene diisocyanate (TDI), a major cause of occupational 536 
asthma, demonstrated the involvement of miR-210 via inhibitory effects on Treg function, 537 
particularly during the sensitisation phase of TDI-induced allergic asthma (Long et al. 2016).  538 
 539 
Tang et al., identified roles for miR-21a-3p, miR-449c-5p, and miR-496a-3p in mouse models 540 
of asthma, and identified an miR-21/Acvr2a axis in regulating asthma-induced inflammation 541 
(Tang et al. 2016). Also, we have shown crucial roles for miR-21 in the pathogenesis of an 542 
experimental mouse model of steroid-insensitive asthma. It’s effects occur though the 543 
suppression of anti-inflammatory phosphatase and tensin (PTEN) homolog, that increases the 544 
phosphoinositide 3-kinase (PI3K) signal, in turn reducing histone deacetylase-2 levels that are 545 
required for responses to steroid treatment (Kim et al. 2017a). Elbehidy et al., confirmed miR-546 
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21 as a potential novel biomarker for asthma diagnosis in children (Elbehidy et al. 2016). miR-547 
10a has also been identified as a possible therapeutic target in regulating the proliferation of 548 
ASM cells via the PI3K pathway (Hu et al. 2014). Xiang and colleagues demonstrated the role 549 
of miR-487b in activating and regulating macrophages in innate immune responses including 550 
pro-inflammatory effects through the induction of IL-33 transcripts (Xiang et al. 2016). 551 
Another study showed that antagonising miR-328 in the infected lung enhances the 552 
antimicrobial potential of macrophages and neutrophils along with the clearance of Non-553 
typeable Haemophilus influenzae (Tay et al. 2015). 554 
 555 
A primary pathogenic factor in asthma is the overexpression of IL-13, and most miRNAs 556 
implicated in the disease, such as miR-133a, -145, -126, -155 and -146, contribute to its 557 
regulation (Chiba et al. 2009; Collison et al. 2011; Greene and Gaughan 2013; Liu et al. 2015; 558 
Matsukura et al. 2016). Ho et al., showed in an ovalbumin-induced mouse model of asthma 559 
that diallyl sulfide has protective effects due to miR-144, -34a and -34b/c induced Nrf2 560 
activation, which has anti-oxidant effects (Ho et al. 2016). miR-19a has been identified as a 561 
potential new therapeutic target for the management of severe asthma, where its 562 
downregulation controls epithelial repair (Haj-Salem et al. 2015). Likewise, knock down of 563 
miR-106a suppressed airway inflammation, goblet cell metaplasia, sub-epithelial fibrosis and 564 
AHR in a mouse asthma model (Sharma et al. 2012). 565 
 566 
As well as miRNAs, long non-coding RNAs (LncRNAs), such as LncRNAs BCYRN1, 846, 567 
or 4176 have also been implicated in airway inflammation and could be therapeutic targets in 568 
asthma (Wang et al. 2017; Zhang et al. 2016). 569 
 570 
Novel drug delivery systems 571 
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The application of novel drug delivery systems is gaining popularity for the treatment of 572 
various chronic lung diseases, including asthma (Mehta et al. 2020a; Mehta et al. 2020b; 573 
Prasher et al. 2020). These include nanoparticle-based drug delivery, dry powder inhalers, 574 
micelle pharmacosomes, liposomes, dendrimers, and antibody-mediated drug delivery systems 575 
(Lanza et al. 2017).  576 
Nanoparticles: A recent study evaluated the in vivo efficacy of biocompatible nanoparticles 577 
targeting IL-4Rα. These particles have enhanced permeability, and reduced lung inflammation 578 
and improved the immunosuppressive effects of anti-IL4Rα in ovalbumin-sensitised mice 579 
(Halwani et al. 2016; Maret et al. 2007). Other studies employed anti-IL-4Rα-blocking 580 
antibodies bound to superparamagnetic iron oxide nanoparticles, using polyethylene glycol 581 
polymers. These nanocarriers have improved targeting effects on various inflammatory cells 582 
(Al Faraj et al. 2016). Another study developed strontium-doped hydroxyapatite porous 583 
spheres (SHAS), an adjuvant and carrier in allergen-specific immunotherapy, where they have 584 
showed that the subcutaneous injection of allergen (OVA) stimulates both CD4+ and CD8+. 585 
The treatment of SHAS-OVA has proven better in efficacy as compared to soluble OVA alone 586 
with no necrotic or apoptotic effects (Garbani et al. 2016) . 587 
One of the latest advances are protein corona (the outer layer of proteins adsorbed onto the 588 
nanoparticles), which are combined with inhaled nanoparticles to facilitate their movement 589 
through the respiratory tract, particularly the lining fluid. The corona contains various innate 590 
immune proteins like surfactant protein A, napsin A and complement (C1q, C3) (Shahabi et al. 591 
2015). Inhaled nanoparticles often acquire a layer of protein corona as they pass through the 592 
respiratory tract. The identification of individual components of protein corona would improve 593 
their use with inhaled nanoparticles in therapeutics. Investigations are underway to identify 594 
types of proteins and the mechanisms involved. A recent attempt undertook proteomic and 595 
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lipidomic analysis to define the composition of the surfactant corona on inhaled nanoparticles 596 
(Raesch et al. 2015). 597 
Liposomes: Alternative drug delivery modes include liposomes, which are spherical vesicles 598 
of lipid bilayers. Maret et al., used all-trans retinoic acid encapsulated liposomes in a mouse 599 
model of ovalbumin-induced allergic airways disease, which reduced the synthesis of IgE and 600 
airway inflammation (Maret et al. 2007). Similarly, the efficacy of budesonide in stealth 601 
liposomal formulations is greater than the drug alone at reducing lung inflammation (Konduri 602 
et al. 2003). Liposomal formulations encapsulated with procaterol hydrochloride have 603 
sustained release and potent pharmacological effects on pulmonary administration (Tahara et 604 
al. 2016). Also, various liposomes can combat the problem of bacterial biofilms in asthma 605 
(Bandara et al. 2016; Liu and Post 2009). Other studies used liposomal formulations with 606 
various other therapeutic moieties, including amphotericin B, ciprofloxacin, topotecan, and 607 
calcifediol against different infections including Aspergillosis and Pseudomonas infection 608 
(Adhikari et al. 2015; Castoldi et al. 2016; Saraf et al. 2016). Blom et al., developed a triple 609 
co-culture model of epithelial cells, macrophages, and DCs to mimic the human respiratory 610 
tract to better understand the immuno-modulatory effects of novel drug delivery systems, such 611 
as liposomes and virosomes. These advanced drug delivery modes have proven as a great 612 
antigen carriers demonstrating lesser inflammation and controlling the mucosal immune 613 
responses (Blom et al. 2016). 614 
Other drug delivery systems: Mucoadhesion of drugs is an important aspect of drug delivery 615 
in airway diseases, particularly asthma. Co-adhesive microspheres of levosalbutamol sulphate 616 
were prepared using spray drying techniques. Microspheres demonstrated sustained release of 617 
Levosalbutamol Sulphate because of their particle size, swell-ability, and increased 618 
mucoadhesion features (Patel et al. 2012). Similarly, chitosan-based microspheres containing 619 
montelukast sodium have been used, and have effective physicochemical properties required 620 
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for optimal pulmonary drug delivery (Dua et al. 2017a; Panchal et al. 2012). Pachuau et al., 621 
used solvent evaporation to prepare matrix microspheres with salbutamol sulphate and 622 
theophylline for simultaneous delivery to induce prolong and sustained release (Pachuau et al. 623 
2008). Gelatin microspheres are another important category and have improved mucoadhesive 624 
and sustained release properties with drugs like salbutamol sulphate (Jayan et al. 2009) . Both 625 
of these studies outcomes provide insight into reducing the frequency of drug administration 626 
resulting in better patient compliance. 627 
 628 
Recent reports highlight the relevance of advanced drug delivery systems, such as liposomes 629 
and nano/macro particles, for the pulmonary delivery of heparin (Yildiz-Pekoz and Ozsoy 630 
2017). Yhee et al., postulated that nanoparticle-based drug delivery is an advanced platform to 631 
achieve maximum therapeutic efficacy in asthma, COPD, cystic fibrosis, idiopathic pulmonary 632 
fibrosis, and lung cancers (Yhee et al. 2016). Another promising means of delivery in targeting 633 
and overcoming the mucus barrier is nanocomplexes for gene therapy, which are in clinical 634 
trials (Di Gioia et al. 2015). Other novel drug delivery modalities have been investigated in 635 
asthma, including chrono-modulated drug delivery, dendrimers, and micelles (Nasr et al. 2014; 636 
Peng et al. 2015; Qureshi et al. 2008). All are advancing respiratory drug delivery, allowing 637 
translation of therapeutic moieties into clinically effective and patient-friendly drug delivery 638 
systems by reducing the associated side effects, reduced frequency of drug administration, 639 
targeted effects and better patient adherence to the dosage regime. 640 
 641 
Conclusions 642 
Mild-to-moderate allergic asthma is underpinned by allergen-induced IgE and type 2 643 
eosinophilic inflammation that causes airway tissue remodelling and AHR. However, 644 
neutrophilic and non-eosinophilic severe steroid-resistant asthma is now recognised that is 645 
driven infection or other exposures that induce Th1/Th17 dominant responses. Understanding 646 
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the pathogenesis of these different forms of asthma enables the development of precision 647 
therapies that target the different endotypes. Consequently, biological have been developed for 648 
allergic asthma that target IgE and type 2 responses during the sensitisation (TSLP, IL-33, IL-649 
4) or developed (IL-5, IL-13, IL-4Ra) phases of disease. New therapies that target more severe 650 
neutrophilic steroid non-responsive phenotype that target type I (TNF/PDEI) and neutrophilic 651 
inflammation (IL-17) or infection-induced processes (macrolides) show promise but are less 652 
well established. Recent advances have revealed the novel roles and significant involvement 653 
of vascularisation and miRNAs in asthma pathogenesis. Angiogenesis and vascularisation in 654 
the pulmonary system increase and provide vessels for the delivery of more inflammatory cells 655 
and greater levels on inflammation. Thus, targeting pro-vascularisation factors (VEGF) or 656 
using suppressors (endostatin, tumstatin) may have beneficial effects. Other novel potential 657 
therapies target miRNAs that control the expression of genes relevant to asthma. Targeting 658 
specific miRNA with inhibitors may also be beneficial in asthma by; reducing specific pro-659 
inflammatory cytokine and chemokine expression, including IL-13 signalling and more 660 
broadly by suppressing nuclear factor-κB signalling, altering the balance between Th1 and Th2 661 
responses, improve regulatory T cell function, reduce mucus hypersecretion, ASM 662 
proliferation and fibrosis and macrophage responses, and increase steroid responses and 663 
epithelial repair in severe asthma.By targeting such factors, new and effective therapeutic 664 
strategies can be developed for asthma. Incorporating new therapeutic agents into novel drug 665 
delivery systems including nanoparticles, liposomes and other delivery systems could enhance 666 
specific targeting of specific cell types to improve disease management and patient compliance. 667 
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TABLE 1 Evidence for increased vascularisation in asthma 674 
Feature Measures Reference 
Increased amount 
of blood vessels, 
vessel density and 
vascular area 
Microscopic evaluation of bronchial biopsy specimens revealed 
significantly higher amounts of microvessels in the lamina 
propria of asthma patients. Increased numbers of mast cells 
also detected. Control patients had scattered and less 
microvessel density. Intensity of microvascularization was 





 Bronchial biopsies from asthma patients had a high degree of 
airway vascularity. 
(Hashimoto 






Elevated levels of 
pro-angiogenic 
factors 
Elevated levels of VEGF and angiotensin in sputum 




High levels of VEGF in sputum of asthma patients, reduced by 
inhaled beclomethasone treatment (800μg/day). 
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TABLE 2 Potential biological agents in clinical trials/development for asthma treatment 677 
Drug Mechanism of action Observed Clinical Effect Trial Phase Reference 
Omalizumab Anti-IgE mAb Reduces asthma 
exacerbations  
Approved 













Anti-TSLP mAb  Reduces asthma 
exacerbations  








ANB020 Anti-IL-33 mAb Reduces asthma 
exacerbations 
Phase I (Londei et 
al. 2017) 
 
Dupilumab Anti-IL-4Rα mAb Reduces asthma 
exacerbations 
Increases lung function 
Phase III (Castro et 
al. 2018; 








Pascolizumab Anti-IL-4 mAb No significant clinical 
efficacy 
Phase II (Hart et al. 
2002) 
Altrakincept Anti-IL-4 mAb No significant clinical 
efficacy 
Phase II (Hendeles 
et al. 
2004) 












Benralizumab Anti-IL-5 mAb Reduces peripheral 
eosinophil levels 









Tralokinumab Anti-IL-13 mAb Inconsistent clinical 
effects in reducing asthma 
exacerbation rate  
Phase III (Panettieri 
et al. 
2018; 
Piper et al. 
2013) 
 
Anrukinzumab Anti-IL-13 mAb Reduces allergen-induced 
asthmatic responses 
Phase II (Hua et al. 
2015) 
Lebrikizumab Anti-IL-13 mAb Inconsistent clinical 
effects in reducing asthma 
exacerbation rate 
Significant adverse 
effects, including aplastic 
anaemia and eosinophilia 
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Figure Legends 680 
FIGURE 1 Comparison between the normal and asthmatic lung. Healthy individuals have 681 
normal airway walls and relaxed airway smooth muscle. The airways of asthmatic patients 682 
constrict upon exposure to innocuous antigens, over express mucus, are inflamed with swollen 683 
walls and tightened smooth muscle.  684 
 685 
FIGURE 2 Cascade of events leading to airway inflammation and asthma pathogenesis. 686 
Immunogenic antigens in the air, such as viruses, microbes, and allergens trigger inflammatory 687 
cascades. Activated inflammatory cells, including mast cells, eosinophils and neutrophils 688 
subsequently release a plethora of inflammatory mediators. These mediators drive airway 689 
tissue remodelling and asthma pathogenesis.  690 
 691 
 692 
  693 
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